26 results were returned
The Patents Court has refused to grant an Arrow declaration following de-designation of UK from pending patent applications because there was no uncertainty about UK patent rights and the true purpose of the declaration ...
The European Court of Justice (ECJ) has ruled that a product composed of several active ingredients with a combined effect may be protected by a basic patent in force under the Supplementary Protection Certificate (SPC) ...
The draft amended Patent Law contains several other new provisions in addition to the Patent Linkage and the SPP provisions, such as the draft Article 24 which proposes a six month grace period of novelty for an ...
In the wake of the COVID-19 pandemic the German government has recently passed a “corona crisis package”. The so-called Act for protecting the Population in the Event of an Epidemic Situation of National Importance, the ...
Today the Court of Justice of the European Union (CJEU) handed down its decision in the Royalty Pharma case concerning the interpretation of Art. 3 a of Regulation EC 469/2009 on Supplementary Protection Certificates ...
Almost two years ago, the Higher Regional Court Düsseldorf first iterated new liability criteria with respect to Second Medical Use Patents (cf. decision Östrogenblocker of May 5, 2017, docket no. I-2 W 6/17).
The Patents Court has considered enablement in relation to anticipation of a claimed monoclonal antibody invention by prior art, and held the patent was invalid for lack of novelty; it was also obvious for lack of ...
The Supreme Court has confirmed that a patent for a dosage regime of a drug used to treat erectile dysfunction (ED) was obvious over the prior art.
The United Kingdom Supreme Court (UKSC) today handed down its judgment in the case of Actavis UK Limited and others v Eli Lilly and Company ([2017] UKSC 46) that has significantly changed the law of patent infringement ...
DEFAULT DEFAULT Most Relevant Alphabetical Chronological Go
REFINE RESULTS: